Clinical Trial Update: Efficacy and Safety of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating LX101 for inherited retinal dystrophy due to RPE65 mutations reports on efficacy and safety; the study is currently active b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inherited Retinal Dystrophy Associated with Rpe65 Mutations

Drugs mentioned

• LX101

Snippet

Sponsor: Innostellar Biotherapeutics Co.,Ltd | Conditions: Inherited Retinal Dystrophy Associated With RPE65 Mutations | Phase 3 | Status: ACTIVE_NOT_RECRUITING